UK medical device company signs agreement to distribute products in Australia

Medical device company, Biocomposites, has signed an exclusive agreement with LifeHealthcare to sell its Stimulan and genex products in Australia.

Biocomposites engineers, manufactures, and markets products for use in infection management in bone and soft tissue all around the world.

LifeHealthcare is an Australian provider of medical device solutions. The organisation has a team of orthopaedic experts that focus on infection, revision arthroplasty, oncology, limb deformity, paediatrics, and biologics.

The Stimulan Rapid Cure and Stimulan Kit products are absorbable and specifically designed to be placed at the site of infection as part of a surgeon’s dead space and infection management strategies. Its unique crystal structure and properties claim to transform outcomes in the presence of infection. The genex platform is a versatile synthetic bone graft that supports natural healing and vanishes without a trace.

Michael Harris, chief executive officer of Biocomposites, said: “Partnering with LifeHealthcare allows us to provide surgeons treating infected and high-risk patients with our innovative products - to improve patient outcomes, reduce hospital readmissions and lower overall treatment costs. This is another example of our strategy to partner with key players in our priority markets, which already includes agreements with the NHS in the UK and HealthTrust in the US.”

Matt Muscio, chief executive officer of LifeHealthcare, added: “We are very pleased to collaborate with Biocomposites to further address the needs of Australian surgeons and their patients.

“LifeHealthcare has established an excellent distribution presence and our strong relationship with surgeons enables us to effectively bring best in class products such as Stimulan to market. This product fits well into our portfolio of complex arthroplasty and oncology solutions and we look forward to working with the Biocomposites team into the future.”